TAKE’s Chief On ‘New Normal’ For CRO Audits, Outcome-Based Pricing
TAKE Solutions’ managing director outlines in an interview with Scrip a range of issues shaping the clinical research segment, including the "humongous" number of audits firms face against the backdrop of compliance woes in the sector, the “reach-out” from Chinese firms amid evolving regulations and a potential shift to outcome-based pricing in the CRO space.
You may also be interested in...
More Indian companies are headed to China, with Cipla the latest to seal a joint venture there, though the firm has previous links with the country. Respiratory products will lead Cipla’s line-up in China, a market seen as a crucial cog in the firm’s future road map.
India’s new clinical trial regulations could revive sponsor interest in the country, but some norms around local Phase III trial waivers appear open to interpretation and could potentially weigh down momentum.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.